OGEN

Oragenics, Inc. (OGEN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Oragenics, Inc. is a development-stage biopharmaceutical company focused on nasally delivered therapies for neurological conditions. Its lead product candidate, ONP-002, is a synthetic neurosteroid intended for the treatment of mild traumatic brain injury (concussion). The company is currently advancing ONP-002 toward Phase 2a clinical trials in Australia and New Zealand.

Corporate Action: On June 3, 2025, the Company effected a 1-for-30 reverse stock split. All share and per-share amounts in this filing have been retroactively adjusted to reflect this split.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 25.7% in Q2 2025 compared to Q2 2024 ($1.71M vs. $2.31M). This reduction was driven primarily by a 50.4% decrease in R&D expenses ($0.45M vs. $0.91M), as the company shifted focus solely to ONP-002 regulatory submissions, whereas the prior year included costs for vaccine and antibiotic programs.
• Interest Expense: Interest expense surged to $0.57 million in Q2 2025 from $1,803 in Q2 2024. This increase is due to the amortization of debt discount and closing costs associated with a $3.0 million promissory note issued in March 2025.
• Liquidity: Cash and cash equivalents increased to $1.97 million from $0.86 million at year-end 2024, driven by financing activities offsetting operating cash burn.

Outlook, Risks, and Subsequent Events

Subsequent Financing (Critical): On July 2, 2025, the Company completed a public offering of Series H Convertible Preferred Stock and warrants, raising approximately $15.2 million in net proceeds. This capital was used to repay the $3.0 million promissory note in full and is expected to extend the company's cash runway into the first half of 2026.

Going Concern: The filing includes an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern due to recurring losses and an accumulated deficit of $221 million. While the July 2025 financing mitigates immediate liquidity risk, the Company states that substantial doubt remains unless additional capital is secured for operations beyond the current planning horizon.

Risks & Contingencies:

• Legal Proceedings: The Company is involved in a dispute with Ladenburg Thalmann regarding a $2.5 million fee claim related to a 2023 asset purchase. The Company denies the claim, and arbitration is scheduled for late September 2025.
• Dilution: The Series H Preferred Stock contains anti-dilution provisions that could lower the conversion price in future offerings, potentially resulting in significant dilution to common shareholders.
• Capital Needs: Additional funding will be required to complete Phase 2 trials and commercialization. Failure to secure this capital could force the delay or elimination of R&D programs.

Investor Verification Checklist

• Verify the terms and anti-dilution provisions of the Series H Preferred Stock issued in July 2025 and their potential impact on common share dilution.
• Confirm the status of the Ladenburg Thalmann litigation and the potential financial exposure of the $2.5 million claim.
• Monitor the timeline for the initiation of the Phase 2a clinical trial for ONP-002 in Australia/New Zealand, currently estimated for Q3 2025.
• Assess the sufficiency of the $15.2 million raised in July 2025 to fund operations through the first half of 2026, given the company's historical burn rate.
• Review the impact of the 1-for-30 reverse stock split on trading liquidity and market price.